The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine (Q46803184)

25 December 2017

title

The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine (English)

1 reference

25 December 2017

main subject

patient

0 references

acute coronary syndrome

1 reference

5

1 reference

25 December 2017

author name string

Ewa Karwatowska-Prokopczuk

1

1 reference

25 December 2017

Whedy Wang

2

1 reference

25 December 2017

Mei L Cheng

3

1 reference

25 December 2017

Dewan Zeng

4

1 reference

25 December 2017

Luiz Belardinelli

6

1 reference

25 December 2017

publication date

19 December 2012

1 reference

25 December 2017

published in

EP Europace

1 reference

25 December 2017

volume

15

1 reference

25 December 2017

issue

3

1 reference

25 December 2017

page(s)

429-436

1 reference

25 December 2017

Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Sudden cardiac death and the role of medical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Risk stratification in the long-QT syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Prolonged QTc interval and risk of sudden cardiac death in a population of older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Assessing predictors of drug-induced torsade de pointes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Electrophysiologic basis for the antiarrhythmic actions of ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

Estimating the Dimension of a Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

QT interval and mortality from coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUS400

21 January 2018

Identifiers

DOI

10.1093/EUROPACE/EUS400

1 reference

25 December 2017

PubMed ID

23258816

1 reference

25 December 2017